Toshihiko Doi
Chiba, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 200 publications
A Phase 1 Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients With Advanced Gastrointestinal Cancers.
Journal: Cancer research communications
Published: February 04, 2026
First-line pembrolizumab plus chemotherapy versus chemotherapy alone for advanced esophageal cancer: 5-year extended follow-up in the Japanese subgroup of KEYNOTE-590.
Journal: Esophagus : official journal of the Japan Esophageal Society
Published: January 08, 2026
Zanidatamab, a Dual HER2-Targeted Bispecific Antibody, in Patients with Unresectable Locally Advanced or Metastatic HER2-Positive Salivary Gland Cancer: A Combined Analysis of Early-Phase Studies.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 20, 2025
Study protocol for a phase I investigator-initiated clinical trial of E7820 in Japanese patients with unresectable solid tumours: CIRCUS trial (NCCH2303).
Journal: Japanese journal of clinical oncology
Published: November 16, 2025
Potent antitumor efficacy of datopotamab deruxtecan compared with sacituzumab govitecan in an intracranial tumor model of triple-negative breast cancer.
Journal: Molecular cancer therapeutics
Published: October 05, 2025
Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study.
Journal: ESMO open
Published: July 25, 2025
Pimitespib for advanced gastrointestinal stromal tumor: a plain language summary of the CHAPTER-GIST-301 study.
Journal: Future oncology (London, England)
Published: July 11, 2025
Erdafitinib in Patients with FGFR-Altered Advanced or Metastatic Cholangiocarcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 17, 2025
Trial in progress: phase I study of non-viral gene-modified CAR-T cell therapy for malignant solid tumors expressing EPHB4 receptor (CARTiEr).
Journal: Frontiers in oncology
Published: May 22, 2025
Ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial.
Journal: The Lancet. Oncology
Published: March 03, 2025
Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors.
Journal: Future oncology (London, England)
Published: January 16, 2025
Last Updated: 09/26/2026